EquitiesAmerica.com
Fundamental AnalysisRerequired return on equity

Cost of Equity

Cost of equity is the return that equity investors require to compensate them for the risk of owning a company's shares, representing the opportunity cost of capital for equity-financed investments.

Formula
Re = Rf + Beta x (Rm - Rf) [CAPM]

Unlike debt, equity carries no contractual payment obligation, so there is no observable 'price' analogous to a bond yield. Instead, the cost of equity must be estimated, and the most widely used framework in US practice is the Capital Asset Pricing Model (CAPM). The CAPM formula is: Re = Rf + Beta x (Rm - Rf), where Rf is the risk-free rate (typically the 10-year US Treasury yield), Beta measures the stock's sensitivity to broad market movements, and (Rm - Rf) is the equity risk premium (ERP) — the additional return investors demand for holding equities over risk-free assets.

As a concrete example, suppose the 10-year Treasury yields 4.5%, a company's beta is 1.2, and the long-run ERP is estimated at 5%. Cost of equity = 4.5% + 1.2 x 5% = 10.5%. This means equity investors in this company require roughly 10.5% annual return to hold the stock instead of investing in Treasuries.

Alternative approaches exist. The dividend discount model (DDM) back-solves for the discount rate: Re = D1 / P0 + g, where D1 is the next expected dividend, P0 is the current stock price, and g is the sustainable long-run dividend growth rate. This is more appropriate for mature dividend payers like Coca-Cola or Johnson & Johnson than for growth companies that pay no dividends. The Fama-French multi-factor model adds size and value premia to CAPM for a richer (if more parameter-intensive) estimate.

The cost of equity is always higher than the cost of debt for the same firm because equity is a junior claim — in bankruptcy, equity holders are paid only after all creditors. This subordination demands a premium. For US companies, cost of equity typically ranges from 7% for low-beta utilities to 15% or more for high-beta technology or biotech firms. Because cost of equity is the largest component of WACC for equity-heavy companies, small errors in the beta or ERP assumption ripple through the entire DCF valuation. Analysts frequently run sensitivity tables varying the cost of equity by plus or minus 1-2 percentage points to understand the range of outcomes.

Another use is benchmarking return on equity (ROE) against cost of equity. If a company earns an ROE above its cost of equity, it is creating shareholder value; if ROE falls below, it is destroying value even while reporting positive net income.

Learn more on EquitiesAmerica.com

Educational only. This glossary entry is for informational purposes and does not constitute investment, tax, or legal guidance. Please consult a registered investment professional before making any investment decision.